Pay in 4 interest-free payments of $5.85 Learn more
Ships within 48 hours · Estimated delivery Aug 6 - Aug 11
Alexander Kokkinos Carel Le Roux To view or add a comment, sign in Tirzepatide: Redefining Outcomes in Diabetes & Obesity Care Clinical trials show tirzepatide, a dual GIP/GLP-1 receptor agonist, is delivering results beyond expectations: Up to 20.9% mean weight loss at 72 weeks (SURMOUNT-1, NEJM) 94% risk reduction in progression from prediabetes to type 2 diabetes over 3 years Superior HbA1c reduction and weight control vs leading GLP-1 therapies (SURPASS program) With manageable side effects and durable outcomes, tirzepatide is reshaping how we approach metabolic disease
Talk to a Physicians Plan provider about whether a treatment is right for you.
At TrimRx, we are committed to providing a holistic and personalized approach to weight loss
At 55, 214.5 lbs, 7.8% body fat recorded April 17, 2026
The BUD is determined by the pharmacy based on USP (United States Pharmacopeia) guidelines and their own stability testing
The herbal wellness patch category is not equivalent to prescription GLP-1 medications
US$ 28.59
US$ 24.76
US$ 26.70
US$ 21.52
